Myeloid's Precision Medicine & Biomarkers team is growing.?We are seeking a dynamic Biomarker Scientist/Senior Scientist to take us even further. Check out our job posting for more information. https://lnkd.in/eF3jN-yV
关于我们
At Myeloid, we have applied our extensive knowledge of advanced gene and cell therapies to build novel platform technologies that harness the innate abilities of myeloid cells. We have translated the learnings from our backgrounds and novel platform to create a clinical-stage, mRNA-immunotherapy pipeline focused on breakthrough therapies for cancer. We invite you to join us on this journey – patients are waiting.
- 网站
-
https://www.myeloidtx.com
Myeloid Therapeutics的外部链接
- 所属行业
- 生物技术
- 规模
- 11-50 人
- 总部
- Cambridge，Massachusetts
- 类型
- 私人持股
地点
-
主要
获取路线
300 Technology Sq
2nd Floor
US，Massachusetts，Cambridge，02139
Myeloid Therapeutics员工
动态
-
2025 is set to be our most exciting year yet. Tune in on Wednesday to learn more about our progress towards conquering solid tumors with invivo mRNA CAR technology.
Next week at #JPM2025, our CEO Daniel G., Ph.D., will present on Wednesday, January 15, 2025, at 8:30 am PT. Members of the management team will meet with investors one-on-one to discuss our industry-leading in vivo mRNA engineering technology. Read more here: https://lnkd.in/gFPWYJRG #Biotech #mRNA??
-
-
Next week at #JPM2025, our CEO Daniel G., Ph.D., will present on Wednesday, January 15, 2025, at 8:30 am PT. Members of the management team will meet with investors one-on-one to discuss our industry-leading in vivo mRNA engineering technology. Read more here: https://lnkd.in/gFPWYJRG #Biotech #mRNA??
-
-
The Myeloid Therapeutics team is looking forward to participating in the Jefferies London Healthcare Conference beginning November 19, 2024. Members of the management team will meet with investors one-on-one and conduct B-to-B meetings to discuss our industry-leading in vivo mRNA engineering technology. Read more here: https://lnkd.in/gaWX-zQG #Biotech #mRNA #JefferiesHealthcare
-
-
At #SITC2024 today, we are proud to be making an oral presentation on MT-303, our second?in vivo?mRNA CAR program to reach the clinic. Read more here: https://lnkd.in/gEb_7GdS #Biotech #mRNA
-
-
At #SITC2024 today, we are proud to be making an oral presentation on MT-303, our second?in vivo?mRNA CAR program to reach the clinic. Read more here: https://lnkd.in/gEb_7GdS #Biotech #mRNA
-
-
Look out for the Myeloid team at SITC- the team will be discussing the first invivo mRNA car programs to go into humans.
Are you heading to Houston for SITC? Myeloid Therapeutics will be presenting the pre-clinical development of MT-303, a novel LNP-formulated GPC3-specific CAR mRNA, for in vivo reprogramming of monocytes to treat hepatocellular carcinoma. Meet me at poster 1125 tomorrow during lunch break or from 5-7pm, or head to section 107b at 3:50pm to see our CMO Matthew Maurer presenting pre-clinical and clinical data. https://lnkd.in/eGZr4bn8 #SITC #CARmonocytes #myeloidcells #CARm
-
At 9:30 am today, Myeloid Therapeutics’ CEO, Daniel G., PhD, is speaking at #BioEurope in the Immuno-Oncology session. We look forward to showcasing our science and mRNA-based clinical pipeline. Learn more here: https://lnkd.in/dnuNZ2D #Biotech #mRNA
-